(Circulation. 1995;91:764-770.)
© 1995 American Heart Association, Inc.
Articles |
Induction of Plasminogen Activator Inhibitor Type-1 (PAI-1) by Proinsulin and Insulin In Vivo
From the Cardiovascular Division, Washington University School of Medicine, St Louis, Mo, and the Department of Medicine, The University of Vermont College of Medicine, Burlington.
Correspondence to Burton E. Sobel, MD, Department of Medicine, Medical Center Hospital of Vermont, Fletcher House 311, Burlington, VT 05401.
Background Fasting hyperinsulinemia (reflected by elevations in immunoreactive "insulin") is typical of patients with non–insulin-dependent diabetes mellitus (NIDDM) and is often associated with obesity and hypertension. The elevated concentrations detected are indicative not only of insulin but also of its immunologically cross-reactive precursors, including proinsulin. Fasting hyperinsulinemia appears to be associated with decreased fibrinolytic activity in blood, which results from increased activity of plasminogen activator inhibitor type-1 (PAI-1), a potential independent risk factor for coronary artery disease. Patients who were given proinsulin in a previous clinical study by others exhibited an increased incidence of cardiovascular events. Thus, a "proinsulin–PAI-1 axis" may predispose to coronary thrombosis. To define the possible presence of such an axis, this study was designed to determine whether insulin, its precursors, or both increase the concentrations of PAI-1 in rabbits in vivo.
Methods and Results Equimolar proinsulin (n=10), insulin (n=11), C-peptide (n=4), or vehicle alone (n=10) was administered intravenously over 1 hour to euglycemic, conscious rabbits. Plasma PAI-1 activity increased 3.8-fold with proinsulin (P=.002) and 3.6-fold with insulin (P=.002). By contrast, no increase occurred after C-peptide or vehicle was administered. The increased PAI-1 activity was shown to be attributable to PAI-1 protein by reverse fibrin autography. As judged from changes in mRNA in tissues, proinsulin and insulin increased PAI-1 gene expression within 3 hours by 2.1- and 2.1-fold, respectively, in aorta (P=.025 each) and by 1.9- and 2.4-fold in liver (P=.015 and P=.001), with return of values to baseline within 24 hours (n=4 experiments in each case).
Conclusions These results extend our previous observations from studies in vitro and suggest that hyperinsulinemia attributable to augmented concentrations of proinsulin and insulin in plasma increase plasma PAI-1 activity and may contribute to acceleration of atherosclerosis and impairment of coronary thrombolysis in patients with NIDDM.
Key Words: insulin • diabetes mellitus • fibrinolysis
This article has been cited by other articles:
 |
|
 |
|
  L. Brazionis, K. Rowley, A. Jenkins, C. Itsiopoulos, and K. O'Dea Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes: A Different Relationship With Coronary Heart Disease and Diabetic Retinopathy Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 786 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Stegenga, S. N. van der Crabben, M. Levi, A. F. de Vos, M. W. Tanck, H. P. Sauerwein, and T. van der Poll Hyperglycemia Stimulates Coagulation, Whereas Hyperinsulinemia Impairs Fibrinolysis in Healthy Humans Diabetes, June 1, 2006; 55(6): 1807 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Alssema, J. M. Dekker, G. Nijpels, C. D.A. Stehouwer, L. M. Bouter, and R. J. Heine Proinsulin Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality: An 11-year follow-up of the Hoorn Study Diabetes Care, April 1, 2005; 28(4): 860 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Boucher, B. Masri, D. Daviaud, S. Gesta, C. Guigne, A. Mazzucotelli, I. Castan-Laurell, I. Tack, B. Knibiehler, C. Carpene, et al. Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity Endocrinology, April 1, 2005; 146(4): 1764 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Vulin and F. M. Stanley Oxidative Stress Activates the Plasminogen Activator Inhibitor Type 1 (PAI-1) Promoter through an AP-1 Response Element and Cooperates with Insulin for Additive Effects on PAI-1 Transcription J. Biol. Chem., June 11, 2004; 279(24): 25172 - 25178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Sobel, D. J. Taatjes, and D. J. Schneider Intramural Plasminogen Activator Inhibitor Type-1 and Coronary Atherosclerosis Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 1979 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Vaughan Plasminogen Activator Inhibitor-1 and the Calculus of Mortality After Myocardial Infarction Circulation, July 29, 2003; 108(4): 376 - 377. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Doenst, W. Bothe, and F. Beyersdorf Therapy with insulin in cardiac surgery: controversies and possible solutions Ann. Thorac. Surg., February 1, 2003; 75(2): S721 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Stadtmauer, B. C. Wong, and S. Oehninger Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Cefalu, D. J. Schneider, H. E. Carlson, P. Migdal, L. Gan Lim, M. P. Izon, A. Kapoor, A. Bell-Farrow, J. G. Terry, and B. E. Sobel Effect of Combination Glipizide GITS/Metformin on Fibrinolytic and Metabolic Parameters in Poorly Controlled Type 2 Diabetic Subjects Diabetes Care, December 1, 2002; 25(12): 2123 - 2128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Vulin and F. M. Stanley A Forkhead/Winged Helix-related Transcription Factor Mediates Insulin-increased Plasminogen Activator Inhibitor-1 Gene Transcription J. Biol. Chem., May 31, 2002; 277(23): 20169 - 20176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Jayagopal, E. S. Kilpatrick, S. Holding, P. E. Jennings, and S. L. Atkin The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1560 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fink, A. Kazlauskas, L. Poellinger, P. Ebbesen, and V. Zachar Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1 Blood, March 15, 2002; 99(6): 2077 - 2083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bokemark, J. Wikstrand, and B. Fagerberg Intact Insulin, Insulin Propeptides, and Intima-media Thickness in the Femoral Artery in 58-year-old Clinically Healthy Men: The Atherosclerosis and Insulin Resistance Study Angiology, April 1, 2001; 52(4): 237 - 245. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Kario, T. Matsuo, H. Kobayashi, S. Hoshide, and K. Shimada Hyperinsulinemia and hemostatic abnormalities are associated with silent lacunar cerebral infarcts in elderly hypertensive subjects J. Am. Coll. Cardiol., March 1, 2001; 37(3): 871 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lindahl, B. Dinesen, M. Eliasson, M. Roder, G. Hallmans, and B. Stegmayr High Proinsulin Levels Precede First-Ever Stroke in a Nondiabetic Population Stroke, December 1, 2000; 31(12): 2936 - 2941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hammoud, J.-F. Tanguay, and M. G. Bourassa Management of coronary artery disease: therapeutic options in patients with diabetes J. Am. Coll. Cardiol., August 1, 2000; 36(2): 355 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hasdai, C. B. Granger, S. S. Srivatsa, D. A. Criger, S. G. Ellis, R. M. Califf, E. J. Topol, and D. R. Holmes Jr. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb angioplasty substudy J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1502 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Nordt, K. Peter, C. Bode, and B. E. Sobel Differential Regulation by Troglitazone of Plasminogen Activator Inhibitor Type 1 in Human Hepatic and Vascular Cells J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1563 - 1568. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Sakamoto, J. Woodcock-Mitchell, K. Marutsuka, J. J. Mitchell, B. E. Sobel, and S. Fujii TNF-alpha and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes Am J Physiol Cell Physiol, June 1, 1999; 276(6): C1391 - C1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Sobel Increased Plasminogen Activator Inhibitor-1 and Vasculopathy : A Reconcilable Paradox Circulation, May 18, 1999; 99(19): 2496 - 2498. [Full Text] [PDF]
|
|
|
|
|
|
A. Festa, R. D'Agostino Jr, L. Mykkanen, R. P. Tracy, D. J. Zaccaro, C. N. Hales, and S. M. Haffner Relative Contribution of Insulin and Its Precursors to Fibrinogen and PAI-1 in a Large Population With Different States of Glucose Tolerance : The Insulin Resistance Atherosclerosis Study (IRAS) Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 562 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Festa, R. D'Agostino Jr, L. Mykkanen, R. Tracy, B. V. Howard, and S. M. Haffner Low-Density Lipoprotein Particle Size Is Inversely Related to Plasminogen Activator Inhibitor-1 Levels : The Insulin Resistance Atherosclerosis Study Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 605 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Garratt, P. A. Brady, N. L. Hassinger, D. E. Grill, A. Terzic, and D. R. Holmes Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J. Am. Coll. Cardiol., January 1, 1999; 33(1): 119 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Grenett, R. L. Benza, G. M. Fless, X.-N. Li, G. C. Davis, and F. M. Booyse Genotype-Specific Transcriptional Regulation of PAI-1 Gene by Insulin, Hypertriglyceridemic VLDL, and Lp(a) in Transfected, Cultured Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., November 1, 1998; 18(11): 1803 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O C E Gebara, M A Mittleman, B W Walsh, I Lipinska, F K Welty, G Bellotti, J E Muller, F K Sacks, and G H Tofler Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia Heart, September 1, 1998; 80(3): 235 - 239. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. Haffner, R. D'Agostino Jr, L. Mykkanen, C. N. Hales, P. J. Savage, R. N. Bergman, D. O'Leary, M. Rewers, J. Selby, R. Tracy, et al. Proinsulin and Insulin Concentrations in Relation to Carotid Wall Thickness : Insulin Resistance Atherosclerosis Study Stroke, August 1, 1998; 29(8): 1498 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Sobel, J. Woodcock-Mitchell, D. J. Schneider, R. E. Holt, K. Marutsuka, and H. Gold Increased Plasminogen Activator Inhibitor Type 1 in Coronary Artery Atherectomy Specimens From Type 2 Diabetic Compared With Nondiabetic Patients : A Potential Factor Predisposing to Thrombosis and Its Persistence Circulation, June 9, 1998; 97(22): 2213 - 2221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Ruige, W. J. J. Assendelft, J. M. Dekker, P. J. Kostense, R. J. Heine, and L. M. Bouter Insulin and Risk of Cardiovascular Disease : A Meta-Analysis Circulation, March 17, 1998; 97(10): 996 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Byberg, A. Siegbahn, L. Berglund, P. McKeigue, R. Reneland, and H. Lithell Plasminogen Activator Inhibitor-1 Activity Is Independently Related to Both Insulin Sensitivity and Serum Triglycerides in 70-Year-Old Men Arterioscler. Thromb. Vasc. Biol., February 1, 1998; 18(2): 258 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Loskutoff and F. Samad The Adipocyte and Hemostatic Balance in Obesity : Studies of PAI-1 Arterioscler. Thromb. Vasc. Biol., January 1, 1998; 18(1): 1 - 6. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Ehrmann, D. J. Schneider, B. E. Sobel, M. K. Cavaghan, J. Imperial, R. L. Rosenfield, and K. S. Polonsky Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2108 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Nordt, K. Kornas, K. Peter, S. Fujii, B. E. Sobel, W. Kubler, and C. Bode Attenuation by Gemfibrozil of Expression of Plasminogen Activator Inhibitor Type 1 Induced by Insulin and its Precursors Circulation, February 4, 1997; 95(3): 677 - 683. [Abstract] [Full Text]
|
|
|
|
|
|
H. Taegtmeyer Insulin Resistance and Atherosclerosis : Common Roots for Two Common Diseases? Circulation, May 15, 1996; 93(10): 1777 - 1779. [Full Text]
|
|
|
|
|
|
B. E. Sobel Potentiation of Vasculopathy by Insulin : Implications From an NHLBI Clinical Alert Circulation, May 1, 1996; 93(9): 1613 - 1615. [Full Text]
|
|